Anthony C. Tridico Ph.D.
Anthony Tridico is the managing partner of Finnegan's London office. He has more than 15 years of experience in the field of intellectual property law and his practice involves diverse technical areas from biotechnology, chemical and pharmaceutical sciences to medical devices, diagnostic tools, and instrumentation. A significant portion of Dr. Tridico's current practice is devoted to post-grant proceedings, appeals and oral hearings at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), as well as European Patent Office (EPO) opposition and appeal procedures. Dr. Tridico also focuses on international patent prosecution and portfolio management as well as strategic counseling including pre-litigation analysis, due diligence investigations, and the specialized areas of patent term extensions and Orange Book listings.
Working in Europe for much of his career, Dr. Tridico has gained significant knowledge of the European Patent Convention (EPC) and the diversity of laws and practice among the European national systems. His knowledge of the European legal system and how it differs from the United States allows Dr. Tridico to effectively counsel clients with global interests in intellectual property. He has also successfully represented clients in U.S. district court and
multi-national patent litigations including protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations.
Dr. Tridico is a frequent lecturer on intellectual property issues at various international programs and conferences targeted to the U.S. and European business community. He has also spoken before numerous Fortune 500 companies and multi-national organizations throughout the world.
- Currently lead counsel for several clients in the chemical and biotech industries in inter partes review (IPR) post-grant review (PGR) proceedings challenging the validity of competitor patents.
- Successfully represented numerous clients in inter partes reexaminations and ex parte reexaminations post-grant proceedings invaliding competitor patents and helping to clear the way for freedom to operate.
- Currently defending client in an inter partes reexamination and appeal before the PTAB regarding its patent portfolio directed to G-CSF analogs.
- Coordinating European opposition proceedings while providing strategic counseling of the U.S. patent portfolio for a European biotech company regarding a FDA-approved product.
- Provides strategic counseling, patent prosecution, and portfolio management of the global IP portfolio for Capsugel following the $2 billion spin off of the company from Pfizer.
- BTG Int'l v. Kappos (E.D. Va.). Represented BTG in the first post-America Invents Act (AIA) 35 U.S.C. § 145 action in the District Court for the E.D. Virginia on an appeal from the USPTO regarding a patent application directed to CDw52 specific antibodies.
- Represents Pronova BioPharma in Hatch-Waxman litigations against two companies seeking FDA approval to market generic versions of Lovaza® which had 2011 sales of over $900 million. The district court found the asserted patent claims valid, enforceable and infringed in May 2012, thus precluding marketing of any generics until April 2017.
- Regents of the Univ. of California v. Dako (N.D. Cal., Fed. Cir.). Represented Dako in defending against patent infringement allegations involving diagnostic tests for Her2 gene. Successfully defended against a PI motion and later prevailed on summary judgment. On appeal, Federal Circuit affirmed noninfringement of one patent and remanded as to the second patent.
- Adjunct professor at Georgetown University Law School.
- Recognized as a leading patent prosecutor in Belgium by Intellectual Asset Management, 2013; and in London, 2014-2015.
- Sigma Xi.
- IPO Association (European Practice Committee, 2012-present)
- The Chartered Institute of Patent Attorneys (foreign member)
- American Intellectual Property Law Association
- American Chemical Society
- Regular contributor to Full Disclosure, Finnegan's patent prosecution update; and serves as an editor and contributor for Finnegan's AIA blog on PTAB trials and AIA provisions.
- Coauthor. "Covered Business Method Review—Is It Applicable to More Patents Than You Thought?" CIPA Journal, Sept. 2015.
- Coauthor. "Summer USPTO Guidelines Shed Light on the UPSTO's Eligible Subject Matter Analysis," CIPA Journal, Sept. 2015.
- Coauthor. "U.S. Patent Office Published Proposed Rule Change for AIA Trials: So What's New?" CIPA Journal, Sept. 2015.
- Coauthor. "PTAB Affirmance at the Federal Circuit," CIPA Journal, June 2015.
- Coauthor. "What to Consider Before Obtaining and Enforcing a Unitary Patent," Managing Intellectual Property, April 15, 2015.
- Coauthor. "In re Cuozzo: Thumbs Up for the PTAB," CIPA Journal, March 2015.
- Coauthor. "Structure or Function: Which Will Ultimately Have the Most Influence on Patent Eligibility of Biotech Inventions?" CIPA Journal, March 2015.
- Coauthor. "2015—The Year It All Comes Together for The Unified Patent Court," BNA's Patent, Trademark & Copyright Journal, Feb. 13, 2015.
- Coauthor. "What Was Everyone Waiting For? 2014 Interim Guidance on Patent Subject Matter Eligibility," CIPA Journal, Jan. 2015.